Showing 2101-2110 of 2494 results for "".
- Konan Medical Receives CE Marking for ObjectiveFIELD Analyzer (OFA)https://modernod.com/news/konan-medical-receives-ce-marking-for-objectivefield-analyzer-ofa/2484170/Konan Medical USA announced that its objectiveFIELD Analyzer (OFA) has received CE Marking under the European Medical Device Regulation (MDR). The CE Mark enables Konan Medical to offer its next-generation perimetry solution to healthcare providers throug
- Neurolens, Maker of Contoured Prism Technology, Rebrands as Newtonhttps://modernod.com/news/neurolens-maker-of-contoured-prism-technology-rebrands-as-newton/2484138/Neurolens announced its official rebrand to Newton. Named in honor of Sir Isaac Newton, the company said the rebrand reflects Newton’s broader vision to build on its foundation of innovative lens technology and continue driving outcomes that help pa
- PulseSight Therapeutics to Present New Data on Iron Dysregulation and Ferroptosis in AMD at Euretina 2025https://modernod.com/news/pulsesight-therapeutics-to-present-new-data-on-iron-dysregulation-and-ferroptosis-in-amd-at-euretina-2025/2484133/PulseSight Therapeutics announced that its Chief Scientific Officer, Thierry Bordet, PhD, will present new clinical and preclinical findings on the role of iron dysregulation and ferroptosis in age-related macular degeneration (AMD) at the 25th Euretina Congre
- Mark Maire Appointed CEO of Rebionhttps://modernod.com/news/mark-maire-appointed-ceo-of-rebion/2482920/Rebion, a provider of neuro-visual diagnostics and digital retinal imaging technologies, announced the appointment of Mark Maire as Chief Executive Officer. Mr. Maire brings more than two decades of commercial leadership and strategic growth experience, including the sale of TrueVi
- Kowa Initiates Phase 3 Safety Trial for Glaucoma Drug Candidate NCX 470 in Japanhttps://modernod.com/news/kowa-initiates-phase-3-safety-trial-for-glaucoma-drug-candidate-ncx-470-in-japan/2482918/Nicox announced that its exclusive Japanese partner, Kowa, has officially initiated a phase 3 safety clinical trial for NCX 470 (also referred to as K-911) in Japan. NCX 470 is Nicox’s lead clinical candidate, currently undergoing phase 3 clinical evaluations
- Alcon Announces US Launch of Tryptyr for Dry Eye Diseasehttps://modernod.com/news/alcon-announces-us-launch-of-tryptyr-for-dry-eye-disease/2482908/Alcon announced the US commercial availability of Tryptyr (acoltremon ophthalmic solution) 0.003% for the treatment of the signs and symptoms of dry eye disease (DED). Approved by the FDA in May, eye care professionals (ECPs) across the US can officially begin p
- Ziemer USA Announces New Innovations for the Galilei Diagnostic Platform and FEMTO LDV Z8 Femtosecond Laserhttps://modernod.com/news/ziemer-usa-announces-new-innovations-for-the-galilei-diagnostic-platform-and-femto-ldv-z8-femtosecond-laser-platform/2482904/Ziemer USA, in partnership with CorneaGen, announced the launch of the Galilei CTAK module, which is now available for use with the Galilei diagnostic platform. "We are thrilled to complete our product offering for CTAK patients. With the addition of the Galilei CTAK module in combination
- The Vision Council Releases Updated Version of Data Communication Standardhttps://modernod.com/news/the-vision-council-releases-updated-version-of-data-communication-standard/2482899/The Vision Council announced the official release and approval of Version 3.14 of its Data Communication Standard in an effort to advance the efficiency, accuracy, and interoperability of optical manufacturing systems.
- Julia Haller, MD, Named CEO of Wills Eye Hospitalhttps://modernod.com/news/julia-haller-md-named-ceo-of-wills-eye-hospital/2482897/Julia A. Haller, MD, Ophthalmologist-in-Chief at Wills Eye Hospital, will also become the hospital's next Chief Executive Officer. Dr. Haller assumed the expanded leadership post on July 18, succeeding longtime CEO Joseph P. Bilson, who reti
- ViaLase Announces Strategic Leadership Transitionshttps://modernod.com/news/vialase-announces-strategic-leadership-transitions/2482876/ViaLase announced changes to its executive leadership team as the company prepares for commercial launch and regulatory approvals in both the United States and Europe. Tibor Juhasz, PhD, founder and former Chief Executive Officer, has transitioned to